A new MALDI-TOF-based assay for monitoring JAK2 V617F mutation level in patients undergoing allogeneic stem cell transplantation (allo SCT) for classic myeloproliferative disorders (MPD)

Leukemia Research

Volumn 32, Issue 3, 2008, Pages 421-427

  Koren Michowitz, Maya ^a,b   Shimoni, Avichai ^a,b   Vivante, Asaf ^a   Trakhtenbrot, Luba ^a   Rechavi, Gideon ^a,b   Amariglio, Ninette ^a,b   Loewenthal, Ron ^a   Nagler, Arnon ^a,b   Cohen, Yoram ^a,b  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Allo SCT; JAK2 V617F; MALDI TOF; Myeloproliferative disorders

Indexed keywords

JANUS KINASE 2;

ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CONTROLLED STUDY; GENE MUTATION; GENETIC ANALYSIS; HUMAN; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MYELOPROLIFERATIVE DISORDER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SURVIVAL;

ADULT; AGED; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; MUTATION; MYELOPROLIFERATIVE DISORDERS; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; STEM CELL TRANSPLANTATION;

EID: 39749192828     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2007.07.003     Document Type: Article

References (28)

1. McMullin M.F., Bareford D., Campbell P., Green A.R., Harrison C., Hunt B., et al. General haematology task force of the British Committee for Standards in Haematology. Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis. Br J Haematol 130 (2005) 174-195
2. Tefferi A. Essential thrombocythemia: scientific advances and current practice. Curr Opin Hematol 13 (2006) 93-98
3. Guardiola P., Anderson J.E., Bandini G., Cervantes F., Runde V., Arcese W., et al. Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European group for blood and marrow transplantation, Societe Francaise de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study. Blood 93 (1999) 2831-2838
4. Daly A., Song K., Nevill T., Nantel S., Toze C., Hogge D., et al. Stem cell transplantation for myelofibrosis: a report from two Canadian centers. Bone Marrow Transplant 32 (2003) 35-40
5. Deeg H.J., Gooley T.A., Flowers M.E., Sale G.E., Slattery J.T., Anasetti C., et al. Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood 102 (2003) 3912-3918
6. Ditschkowski M., Beelen D.W., Trenschel R., Koldehoff M., and Elmaagacli A.H. Outcome of allogeneic stem cell transplantation in patients with myelofibrosis. Bone Marrow Transplant 34 (2004) 807-813
7. Reilly J.T. Idiopathic myelofibrosis: pathogenesis to treatment. Hematol Oncol 24 (2006) 56-63
8. James C., Ugo V., Le Couedic J.P., Staerk J., Delhommeau F., Lacout C., et al. A unique clonal JAK2 mutation leading to constitutive signaling causes polycythaemia vera. Nature 434 (2005) 1144-1148
9. Baxter E.J., Scott L.M., Campbell P.J., East C., Fourouclas N., Swanton S., et al. Cancer Genome Project. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365 (2005) 1054-1061
10. Levine R.L., Wadleigh M., Cools J., Ebert B.L., Wernig G., Huntly B.J., et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7 (2005) 387-397
11. Kralovics R., Passamonti F., Buser A.S., Teo S.S., Tiedt R., Passweg J.R., et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352 (2005) 1779-1790
12. Zhao R., Xing S., Li Z., Fu X., Li Q., Krantz S.B., et al. Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem 280 (2005) 22788-22792
13. Wernig G., Mercher T., Okabe R., Levine R.L., Lee B.H., and Gilliland D.G. Expression of JAK2 V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 107 (2006) 4274-4281
14. Lacout C., Pisani D.F., Tulliez M., Gachelin F.M., Vainchenker W., and Villeval J.L. JAK2 V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood 108 (2006) 1652-1660
15. Kralovics R., Teo S.S., Buser A.S., Brutsche M., Tiedt R., Tichelli A., et al. Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of JAK2. Blood 106 (2005) 3374-3376
16. Antonioli E., Guglielmelli P., Pancrazzi A., Bogani C., Verrucci M., Ponziani V., et al. Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. Leukemia 19 (2005) 1847-1849
17. Wolansky A.P., Lasho T.L., Schwager S.M., McClure R.F., Wadleigh M., Lee S.J., et al. JAK2 V617F mutation in essential thrombocythemia: clinical associations and long-term prognostic relevance. Br J Haematol 31 (2005) 208-213
18. Campbell P.J., et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 366 (2005) 1945-1953
19. Speletas M., Katodritou E., Daiou C., Mandala E., Papadakis E., Kioumi A., et al. Correlations of JAK2-V617F mutation with clinical and laboratory findings in patients with myeloproliferative disorders. Leuk Res 31 (2007) 1061-1070
20. Finazzi G., Rambaldi A., Guerini V., Carobbo A., and Barbui T. Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status. Haematologica 92 (2007) 135-136
21. Vannucchi A., Antoniolim E., Guglielmelli P., Pancrazzi A., Bogani C., Pieri L., et al. Influence of the JAK2 V617F mutational load at diagnosis on major clinical aspects in patients with polycythemia vera. Blood 108 (2006) 5 (abstract)
22. Khwaja A. The role of Janus kinases in haemopoiesis and haematological malignancy. Br J Haematol 134 (2006) 366-384
23. Jones A.V., Kreil S., Zoi K., Waghorn K., Curtis C., Zhang L., et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 15 106 (2005) 2162-2168
24. Vannucchi A.M., Pancrazzi A., Bogani C., Antonioli E., and Guglielmelli P. A quantitative assay for JAK2(V617F) mutation in myeloproliferative disorders by ARMS-PCR and capillary electrophoresis. Leukemia 20 (2006) 1055-1060
25. Moliterno A.R., Williams D.M., Rogers O., and Spivak J.L. Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expression. Blood 108 (2006) 3913-3915
26. Kröger N., Badbaran A., Holler E., Hahn J., Kobbe G., Bornhauser M., et al. Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis. Blood 109 (2007) 1316-1321
27. Vivante A., Amariglio N., Koren-Michowitz M., Ashur-Fabian O., Nagler A., Rechavi G., et al. High-throughput, sensitive and quantitative assay for the detection of BCR-ABL kinase domain mutations. Leukemia 21 (2007) 1318-1321
28. Theocharides A., Boissinot M., Garand R., Girodon F., Teo S.S., Lippert E., et al. Myeloid blasts in transformed JAK2-V617F positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood 108 (2006) 375 (abstract)